Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2013 | -564.72 Thousand USD | 53.41% |
| 2012 | -1.21 Million USD | 22.55% |
| 2011 | -1.56 Million USD | 49.88% |
| 2010 | -3.12 Million USD | 62.49% |
| 2009 | -8.32 Million USD | 55.5% |
| 2008 | -18.71 Million USD | 0.9% |
| 2007 | -18.88 Million USD | 28.57% |
| 2006 | -26.43 Million USD | -126.95% |
| 2005 | -11.64 Million USD | -12.2% |
| 2004 | -10.38 Million USD | -31.16% |
| 2003 | -7.91 Million USD | 23.17% |
| 2002 | -10.3 Million USD | 2.68% |
| 2001 | -10.58 Million USD | 7.58% |
| 2000 | -11.45 Million USD | 9.82% |
| 1999 | -12.7 Million USD | -67.11% |
| 1998 | -7.6 Million USD | 16.48% |
| 1997 | -9.1 Million USD | -85.71% |
| 1996 | -4.9 Million USD | -75.0% |
| 1995 | -2.8 Million USD | 66.27% |
| 1994 | -8.3 Million USD | 66.8% |
| 1993 | -25 Million USD | -56.25% |
| 1992 | -16 Million USD | -16.79% |
| 1991 | -13.7 Million USD | -48.91% |
| 1990 | -9.2 Million USD | -2.22% |
| 1989 | -9 Million USD | 30.77% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2014 Q1 | -330.64 Thousand USD | -429.15% |
| 2014 Q2 | -317.12 Thousand USD | 4.09% |
| 2013 Q2 | -352.49 Thousand USD | -2072.93% |
| 2013 Q4 | 100.45 Thousand USD | 133.88% |
| 2013 FY | -564.72 Thousand USD | 53.41% |
| 2013 Q3 | -296.46 Thousand USD | 15.9% |
| 2013 Q1 | -16.22 Thousand USD | 95.31% |
| 2012 Q2 | -189.22 Thousand USD | 12.82% |
| 2012 Q4 | -345.58 Thousand USD | 24.92% |
| 2012 FY | -1.21 Million USD | 22.55% |
| 2012 Q1 | -217.05 Thousand USD | -196.62% |
| 2012 Q3 | -460.3 Thousand USD | -143.26% |
| 2011 FY | -1.56 Million USD | 49.88% |
| 2011 Q2 | -629.64 Thousand USD | -1.03% |
| 2011 Q4 | 224.64 Thousand USD | 141.84% |
| 2011 Q3 | -536.87 Thousand USD | 14.73% |
| 2011 Q1 | -623.19 Thousand USD | -177.22% |
| 2010 Q3 | -733.66 Thousand USD | 23.7% |
| 2010 Q4 | -224.8 Thousand USD | 69.36% |
| 2010 Q1 | -1.2 Million USD | -7.71% |
| 2010 Q2 | -961.54 Thousand USD | 20.0% |
| 2010 FY | -3.12 Million USD | 62.49% |
| 2009 Q2 | -1.98 Million USD | 47.73% |
| 2009 FY | -8.32 Million USD | 55.5% |
| 2009 Q4 | -1.11 Million USD | 21.76% |
| 2009 Q1 | -3.79 Million USD | -2.76% |
| 2009 Q3 | -1.42 Million USD | 28.16% |
| 2008 Q2 | -5.58 Million USD | -13.99% |
| 2008 Q1 | -4.9 Million USD | 3.61% |
| 2008 FY | -18.71 Million USD | 0.9% |
| 2008 Q4 | -3.69 Million USD | 18.26% |
| 2008 Q3 | -4.52 Million USD | 19.09% |
| 2007 FY | -18.88 Million USD | 28.57% |
| 2007 Q4 | -5.08 Million USD | -13.77% |
| 2007 Q1 | -4.17 Million USD | 70.98% |
| 2007 Q2 | -5.14 Million USD | -23.25% |
| 2007 Q3 | -4.47 Million USD | 13.13% |
| 2006 Q1 | -4.04 Million USD | -21.26% |
| 2006 FY | -26.43 Million USD | -126.95% |
| 2006 Q3 | -4.02 Million USD | -1.48% |
| 2006 Q2 | -3.96 Million USD | 1.97% |
| 2006 Q4 | -14.39 Million USD | -257.44% |
| 2005 Q2 | -2.43 Million USD | -5.5% |
| 2005 Q1 | -2.3 Million USD | -45.6% |
| 2005 FY | -11.64 Million USD | -12.2% |
| 2005 Q3 | -3.75 Million USD | -54.59% |
| 2005 Q4 | -3.33 Million USD | 11.15% |
| 2004 Q2 | -3.85 Million USD | -49.92% |
| 2004 Q4 | -1.58 Million USD | 33.37% |
| 2004 Q3 | -2.37 Million USD | 38.4% |
| 2004 Q1 | -2.57 Million USD | -42.77% |
| 2004 FY | -10.38 Million USD | -31.16% |
| 2003 Q2 | -1.88 Million USD | 19.49% |
| 2003 Q4 | -1.8 Million USD | 5.13% |
| 2003 Q3 | -1.89 Million USD | -0.94% |
| 2003 FY | -7.91 Million USD | 23.17% |
| 2003 Q1 | -2.33 Million USD | -5.16% |
| 2002 FY | -10.3 Million USD | 2.68% |
| 2002 Q4 | -2.22 Million USD | 11.75% |
| 2002 Q1 | -2.97 Million USD | -29.99% |
| 2002 Q2 | -2.58 Million USD | 13.01% |
| 2002 Q3 | -2.51 Million USD | 2.77% |
| 2001 Q3 | -2.73 Million USD | 12.53% |
| 2001 Q4 | -2.28 Million USD | 16.23% |
| 2001 FY | -10.58 Million USD | 7.58% |
| 2001 Q1 | -2.43 Million USD | -31.27% |
| 2001 Q2 | -3.12 Million USD | -28.05% |
| 2000 Q4 | -1.85 Million USD | 43.68% |
| 2000 Q2 | -3.57 Million USD | -36.68% |
| 2000 Q1 | -2.61 Million USD | 58.45% |
| 2000 FY | -11.45 Million USD | 9.82% |
| 2000 Q3 | -3.3 Million USD | 7.75% |
| 1999 Q3 | -2.3 Million USD | -35.29% |
| 1999 FY | -12.7 Million USD | -67.11% |
| 1999 Q4 | -6.3 Million USD | -173.91% |
| 1999 Q2 | -1.7 Million USD | 19.05% |
| 1999 Q1 | -2.1 Million USD | 0.0% |
| 1998 FY | -7.6 Million USD | 16.48% |
| 1998 Q3 | -1.7 Million USD | 5.56% |
| 1998 Q1 | -1.8 Million USD | 25.0% |
| 1998 Q4 | -2.1 Million USD | -23.53% |
| 1998 Q2 | -1.8 Million USD | 0.0% |
| 1997 Q1 | -2 Million USD | -205.26% |
| 1997 FY | -9.1 Million USD | -85.71% |
| 1997 Q4 | -2.4 Million USD | -9.09% |
| 1997 Q3 | -2.2 Million USD | 8.33% |
| 1997 Q2 | -2.4 Million USD | -20.0% |
| 1996 Q2 | -1.5 Million USD | -7.14% |
| 1996 FY | -4.9 Million USD | -75.0% |
| 1996 Q4 | 1.9 Million USD | 205.56% |
| 1996 Q3 | -1.8 Million USD | -20.0% |
| 1996 Q1 | -1.4 Million USD | -114.58% |
| 1995 Q3 | -800 Thousand USD | 92.79% |
| 1995 Q1 | -500 Thousand USD | 0.0% |
| 1995 FY | -2.8 Million USD | 66.27% |
| 1995 Q4 | 9.6 Million USD | 1300.0% |
| 1995 Q2 | -11.1 Million USD | -2120.0% |
| 1994 Q2 | -3.5 Million USD | 7.89% |
| 1994 Q1 | -3.8 Million USD | 60.82% |
| 1994 Q4 | -500 Thousand USD | 28.57% |
| 1994 Q3 | -700 Thousand USD | 80.0% |
| 1994 FY | -8.3 Million USD | 66.8% |
| 1993 Q3 | -5 Million USD | -13.64% |
| 1993 Q1 | -5.8 Million USD | -20.83% |
| 1993 FY | -25 Million USD | -56.25% |
| 1993 Q4 | -9.7 Million USD | -94.0% |
| 1993 Q2 | -4.4 Million USD | 24.14% |
| 1992 Q2 | -3.1 Million USD | 6.06% |
| 1992 Q4 | -4.8 Million USD | 4.0% |
| 1992 Q3 | -5 Million USD | -61.29% |
| 1992 Q1 | -3.3 Million USD | 15.38% |
| 1992 FY | -16 Million USD | -16.79% |
| 1991 Q1 | -3.2 Million USD | 77.62% |
| 1991 Q3 | -3 Million USD | -350.0% |
| 1991 Q2 | 1.2 Million USD | 137.5% |
| 1991 FY | -13.7 Million USD | -48.91% |
| 1991 Q4 | -3.9 Million USD | -30.0% |
| 1990 Q4 | -14.3 Million USD | -1200.0% |
| 1990 Q2 | 3.7 Million USD | 3600.0% |
| 1990 Q1 | 100 Thousand USD | 100.9% |
| 1990 Q3 | 1.3 Million USD | -64.86% |
| 1990 FY | -9.2 Million USD | -2.22% |
| 1989 FY | -9 Million USD | 30.77% |
| 1989 Q3 | 1.1 Million USD | 10.0% |
| 1989 Q1 | 100 Thousand USD | 100.75% |
| 1989 Q2 | 1 Million USD | 900.0% |
| 1989 Q4 | -11.1 Million USD | -1109.09% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 57.712% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 88.805% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 96.836% |
| Nascent Biotech, Inc. | -2.22 Million USD | 74.675% |
| Rebus Holdings, Inc. | -664 Thousand USD | 14.951% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.69% |
| Qrons Inc. | -643.67 Thousand USD | 12.266% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -44.961% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.983% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -35.921% |
| Skye Bioscience, Inc. | -13.67 Million USD | 95.869% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.213% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 111.49% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -115.769% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.255% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 80.189% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 63.235% |
| Mesoblast Limited | -84.14 Million USD | 99.329% |
| Marizyme, Inc. | -34.08 Million USD | 98.343% |
| Genus plc | 6.4 Million USD | 108.824% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 105.797% |
| Pharming Group N.V. | -4.87 Million USD | 88.427% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 71.572% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 39.367% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 93.237% |
| ContraFect Corporation | -56.88 Million USD | 99.007% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 87.601% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 59.72% |
| IMV Inc. | -38.67 Million USD | 98.54% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 79.471% |
| MultiCell Technologies, Inc. | -722.81 USD | -78028.831% |
| ONE Bio Corp. | 13.68 Million USD | 104.128% |
| Accustem Sciences Inc. | -3.74 Million USD | 84.926% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.043% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -16.905% |
| Q BioMed Inc. | -3.44 Million USD | 83.61% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 115.953% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 78.507% |
| Biomind Labs Inc. | -1 Million USD | 44.065% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.973% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 80.535% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 91.505% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 69.71% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -1785.427% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 96.442% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 70.779% |
| GB Sciences, Inc. | -1.42 Million USD | 60.245% |
| Alpha Cognition Inc. | -9.7 Million USD | 94.181% |
| HST Global, Inc. | -140.9 Thousand USD | -300.777% |
| CSL Limited | 3.7 Billion USD | 100.015% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 49.798% |
| Halberd Corporation | -75.05 Thousand USD | -652.462% |
| Enzolytics Inc. | -2.14 Million USD | 73.719% |
| Agentix Corp. | -1.37 Million USD | 58.832% |
| Resverlogix Corp. | -12.74 Million USD | 95.57% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 82.176% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.867% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 45.908% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 80.656% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 64.243% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 83.415% |
| AVAX Technologies, Inc. | 6.69 Million USD | 108.438% |
| Zenith Capital Corp. | -8.94 Million USD | 93.685% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.864% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3141.622% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 77.0% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -229.266% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 71.831% |
| Kadimastem Ltd | -3.04 Million USD | 81.425% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 42.613% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 55.038% |
| BioStem Technologies, Inc. | -7.77 Million USD | 92.74% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -211.168% |
| LadRx Corporation | -3.82 Million USD | 85.231% |
| Cell Source, Inc. | -4.32 Million USD | 86.944% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 17.793% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 17.793% |
| NovAccess Global Inc. | -2.46 Million USD | 77.107% |
| Affymax, Inc. | -15.04 Million USD | 96.247% |
| Itoco Inc. | -919.14 Thousand USD | 38.56% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 86.676% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 49.533% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1.834% |
| CytoDyn Inc. | -18.05 Million USD | 96.873% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -2143.635% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -156.601% |
| SYBLEU INC | -149.18 Thousand USD | -278.551% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 68.908% |
| International Stem Cell Corporation | -663 Thousand USD | 14.823% |
| Bioxytran, Inc. | -3.82 Million USD | 85.217% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -972.802% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -2676.416% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.443% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 65.097% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 23.254% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 81.848% |
| Neutra Corp. | -229.48 Thousand USD | -146.082% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 96.78% |
| PureTech Health plc | -146.19 Million USD | 99.614% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 97.372% |
| IXICO plc | -1.43 Million USD | 60.701% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 94.05% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.536% |
| CSL Limited | 3.81 Billion USD | 100.015% |
| Cellectis S.A. | -108.85 Million USD | 99.481% |